OptimizeRx Corporation (OPRX) 股票分析

公司概述

OptimizeRx Corporation functions as a digital healthcare technology provider that leverages advanced machine learning methods to generate dynamic audiences through its Dynamic Audience Activation Platform. The company also utilizes Micro-Neighborhood Targeting to construct consumer audiences while adhering to privacy-first principles, positioning itself within the broader Health Information Services industry under the Healthcare sector. This specialized positioning allows the firm to serve as a critical infrastructure provider for digital marketing within the medical field, focusing on predictive analytics rather than direct patient care. In terms of scale, the company carries a market capitalization of $121.95M and reports annual revenue of $109.43M with an employee base of 132. These figures indicate that OptimizeRx operates as a mid-sized enterprise with a relatively lean operational structure, suggesting high capital efficiency where a significant portion of revenue is generated by a small workforce. The market cap relative to revenue implies a valuation that is not excessively large, reflecting the company's status as a niche player in the digital health ecosystem rather than a dominant market leader with massive scale.

财务健康

The company reports a trailing twelve-month revenue of $109.43M and net income of $5.13M, while EBITDA stands at $16.39M. The substantial gap between the EBITDA figure and the net income reveals a significant impact from interest, taxes, and non-operating expenses, as the net income is less than one-third of the EBITDA. Free cash flow is reported at $16.27M, which demonstrates robust financial flexibility and the ability to generate liquidity even after capital expenditures, a crucial metric for a technology firm. The gross margin stands at 67.3%, indicating a highly scalable business model with strong pricing power or low cost of goods sold relative to sales. Operating margin is recorded at 27.7%, which is healthy for a service-oriented tech company, while the profit margin sits at 4.7%, showing that a large portion of operating earnings is consumed by interest, taxes, or other below-the-line items. Total cash assets amount to $23.36M, compared against total debt of $26.10M, resulting in a debt-to-equity ratio of 20.35, which suggests a slightly leveraged but manageable balance sheet given the low absolute debt levels. The current ratio is 3.04, a figure that indicates strong short-term liquidity and a conservative approach to managing working capital obligations. Furthermore, the Return on Equity is 4.2% and Return on Assets is 4.3%, metrics that reveal modest management effectiveness in generating returns relative to the capital invested, consistent with the company's small market capitalization and specific industry dynamics.

估值评估

OptimizeRx trades with a trailing P/E ratio of 24.07 and a forward P/E of 5.72. The stark difference between these two multiples implies a significant divergence between current earnings performance and future earnings expectations, suggesting the market anticipates a dramatic shift in profitability or a temporary earnings anomaly in the current period. The price-to-book ratio is 0.95, which indicates that the stock is trading at a discount to its book value, suggesting the market does not assign a premium to the company's intangible assets or future growth potential at this valuation. Additionally, the price-to-sales ratio is 1.11 and the EV/EBITDA stands at 7.61, providing alternative perspectives that suggest the company is valued reasonably relative to its revenue and cash-generating capabilities despite the low P/E. The stock has a 52-week high of $22.25 and a 52-week low of $5.54, meaning the current trading price sits significantly below the recent high and well above the low, reflecting a volatile trading range typical for small-cap health technology stocks. With a beta of 1.28, the company exhibits higher price volatility relative to the broader market, moving more aggressively than the S&P 500 and requiring investors to tolerate greater fluctuations in share price.

Growth & Income

Revenue growth over the last year is recorded at -0.2%, while earnings growth is listed as N/A due to the small absolute size of the net income. The negative revenue growth indicates a stagnation in top-line sales, whereas the lack of reported earnings growth data makes a direct comparison difficult, though the small net income of $5.13M suggests that earnings are highly sensitive to minor revenue fluctuations. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company currently reinvests all earnings into operations or retains them rather than distributing cash to shareholders. This retention strategy is common for small-cap technology firms aiming to fund R&D or expand their platform capabilities without relying on external financing. The overall growth and income profile is characterized by high financial flexibility from strong cash flow but a lack of current income generation through dividends, alongside a recent contraction in revenue that warrants close monitoring of future operational performance.